Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 18/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 17/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30754092 | 0.91 | PTGER4 (0.42) | PTGER4PTGER2 | |
| SCHEMBL30754111 | 0.91 | PTGER4 (0.50) | PTGER4PTGER2 | |
| SCHEMBL30754098 | 0.85 | PTGER4 (0.48) | PTGER4PTGER2 | |
| SCHEMBL30754102 | 0.82 | PTGER2 (0.54) | PTGER4PTGER2 | |
| SCHEMBL30754089 | 0.82 | PTGER2 (0.54) | PTGER4PTGER2 | |
| SCHEMBL30754105 | 0.79 | PTGER4 (0.41) | PTGER4PTGER2 | |
| SCHEMBL30754094 | 0.79 | PTGER4 (0.45) | PTGER4PTGER2 | |
| SCHEMBL30754093 | 0.79 | PTGER4 (0.45) | PTGER4PTGER2 | |
| SCHEMBL4077381 | 0.79 | PTGER4 (0.43) | PTGER4PTGER2 | |
| SCHEMBL30754084 | 0.77 | PTGER4 (0.47) | PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565565-A1 | 1,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | Nxera Pharma UK Limited (GB) | 2025-06-11 | — | — | EP | disclosed |
| WO-2024028601-A1 | 1,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |